Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Commercial

Set Alert for Commercial

Alnylam Offers Flexible Value-Based Deals For Breakthrough RNAi Drug Onpattro

The commercial team is on board and ready to market the first FDA-approved RNAi therapeutic patisiran for hereditary transthyretin-mediated amyloidosis.

Rare Diseases Pharmacy Benefit Management FDA

Generic Drug Sector Struggles Even As The Need For Cheaper Drugs Grows

Lower prices for generic drugs in the US are continuing to drag on revenues of drug makers like Teva, Sandoz, Mylan and Endo. Industry leaders say the US market is stabilizing, but price erosion and other negative factors impacted second quarter financials across the sector. Teva is attempting a turnaround and Mylan is exploring strategic alternatives.
Generic Drugs Sales & Earnings BioPharmaceutical
Advertisement

Companies

Set Alert for Companies

Latest From Companies

Private Longeveron Bets On Stem Cells For Inflammation, Aging Diseases

Emerging Company Profile: The start-up's Phase I and II studies look promising for stem cell therapy in treating aging frailty, a common condition that overlaps with Alzheimer's disease.

StartUps and SMEs Business Strategies

Sensyne Health CEO Drayson Says IPO Will See AI Group To Profitability

Flush with IPO funding, AI-focused healthcare technology group Sensyne Health will now ready additional products and find three more NHS trust partnerships. CEO Lord Drayson spoke to Scrip.

Artificial Intelligence Business Strategies

Bye Bye Vernalis And Another Blow For UK Biotech

Vernalis' decision to switch strategy and enter the US cough-cold market backfired spectacularly and acquirer Ligand is getting hold of what once was a jewel in the UK biotech crown for next to nothing.

M & A Commercial

Perrigo Looks To Spin Out Or Sell Off Rx Business, But Will Separating Generics Add Value?

Perrigo previously saw value in keeping its prescription pharmaceuticals in-house, but now says it will sell off or spin out the topical generics to focus on its over-the-counter brands. Questions remain about whether the company's generics portfolio is valuable enough to stand alone or attract a buyer.

Business Strategies Generic Drugs

Mavenclad Is Merck KGaA Bright Spot As Q2 Sales Slip

With strong quarterly sales of Mavenclad in Europe, and a recent re-filing of the drug with the FDA, Merck KGaA continues to play the waiting game for top-line growth to return as it banks on the new addition to its MS franchise.

Companies Sales & Earnings

With Novo Nordisk Dependent On GLP-1s, Even Perceived Price Pressures Can Hurt

Long-term top-line market forecasts for Novo Nordisk are heavily reliant on its GLP-1 portfolio's potential - so pricing uncertainties, especially in the US,  can unnerve sentiment, as seen when it reported Q2 results.

Commercial Companies
See All

Deals

Set Alert for Deals

Latest From Deals

Deal Watch, Focus On Acquisitions: Emergent Acquires PaxVax, Pair Of Commercialized Vaccines

Emergent gets vaccines for cholera and typhoid fever in PaxVax buyout. By taking over the OvaScience shell to go public, Millendo expects to take lead candidate livelotide into a pivotal study early next year.

Deals M & A

Venture Funding Deals: Alector, Ascentage, Gossamer And Compass Lead Summer Rounds

Compass raises $132m in Series A as it moves from screening to the clinic, and start-up HotSpot Therapeutics comes out of stealth mode with a $45m Series A financing co-led by Atlas Venture and Sofinnova Partners.

Deals Financing

Bayer Targets COPD In Haplogen Antiviral Pact

Respiratory viral infections are a frequent cause of COPD exacerbations and the German major is joining forces with the Austrian biotech and Evotec to find new antivirals to tackle the disease.

Deals Respiratory

Glenmark Spins Out Business To Drive Value

Glenmark has drawn private equity interest for its carved out domestic orthopedic and pain management business as it seeks to fuel growth in these segments and pare debt via the proceeds. A similar strategy may be deployed for the firm's active pharmaceutical ingredients unit.

Commercial Deals

Finance Watch: Investments In Regenerative Therapies Surged In The Second Quarter

Global financings for cell and gene therapy and tissue engineering companies more than doubled in the second quarter; financings for the sector rose 79% in the first half of 2018. Also, Samumed leads recent venture funding deals with a $438m round.

Financing Regenerative Medicine

Evotec Sets Empire Building Sights On Infectious Disease Space

As others shun anti-infectives, Evotec is consolidating its position. Through an alliance with Sanofi it is evaluating new anti-infectives in three areas, and expects soon to advance its first candidate therapeutic into the clinic.

 

Infectious Diseases Clinical Trials
See All

Strategy

Set Alert for Strategy

Latest From Strategy

Orchard Raises Another $150m For Gene Therapy Pot

Having recently got hold of GlaxoSmithKline's gene therapy assets, Orchard has completed another whopping financing which has got observers thinking that an IPO could soon be in the offing.

Financing Rare Diseases

Rough Patch For Lupin, Much Riding On Solosec, Enbrel Biosimilar

An under pressure US business dented Lupin in Q1, with a recovery seen only in the second half of FY19 as new generic products roll out. A ramp-up in on-market products like Solosec in the US and a smooth run to launch for biosimilar Enbrel in Japan and the EU, among other products, could be vital to restore momentum for the Indian firm.

Strategy India

Bye Bye Vernalis And Another Blow For UK Biotech

Vernalis' decision to switch strategy and enter the US cough-cold market backfired spectacularly and acquirer Ligand is getting hold of what once was a jewel in the UK biotech crown for next to nothing.

M & A Commercial

Evotec Sets Empire Building Sights On Infectious Disease Space

As others shun anti-infectives, Evotec is consolidating its position. Through an alliance with Sanofi it is evaluating new anti-infectives in three areas, and expects soon to advance its first candidate therapeutic into the clinic.

 

Infectious Diseases Clinical Trials

Home Gains Buoy Cipla In Q1 But US Momentum Pivotal

A strong run on home turf lifted Cipla in Q1, but US momentum with differentiated launches is what investors are keeping a sharp eye on. A China play in the respiratory space is also on the cards for the Indian firm.
India Commercial

Timing Is Everything As Mereo Still Eyes US Listing

The London-headquartered firm believes that its efficient control of costs and strong data in support of its investigational treatments for rare respiratory, bone and endocrine diseases will attract investors across the Atlantic once it decides to refile for a listing on the Nasdaq.

Strategy Financing
See All

Market Access

Set Alert for Market Access

Latest From Market Access

Pfizer's CEO Is Bullish On Rebate Changes That Could Power New Launches

Ian Read walked away from a meeting with President Trump with a rosy view on drug pricing and rebate reform. He said he expects rebates will be eliminated, but net drug prices will continue to grow. Rebate reform will benefit new drug launches, he predicted.

Policy & Regulation Pricing Debate

Interview: Measured Launch, Long Future For Gilead CAR-T In Europe

Positive recommendations for the approval of CAR-T therapies Yescarta and Kymriah were delivered in Europe in June. Michael Elliott, Gilead Sciences' VP for medical affairs in Europe, spoke to Scrip about the Yescarta launch strategy and the long-term future of CAR-T.

Launches ImmunoOncology

How Ovarian Cancer Maintenance Therapies Stack Up On Costs And Value

With new branded immunotherapy-based double- or triple-drug combinations on the way, there is greater scrutiny of costs and efficiency.

Cost Effectiveness Market Access
See All

Market Intelligence

Set Alert for Market Intelligence

Latest From Market Intelligence

Esmya Review Held Back Gedeon Richter in First Half

Sales of the uterine fibroid therapy, Esmya, sharply declined during the first half of 2018 at Hungary's specialty pharmaceuticals company, but an EU review of a potential association between the drug and liver injury has now been completed.

 

Gynecology & Urology Drug Safety

Otsuka's Guadecitabine Fails in ASTRAL-1 But AML Studies Continue

Otsuka's guadecitabine has missed co-primary endpoints in older treatment-naïve AML patients but it continues to be evaluated in relapsed and refractory patients, in a therapeutic area undergoing considerable innovation.

 

Clinical Trials Cancer

Serious Candida Infections: Scynexis's Oral Antifungal Could Challenge Fluconazole

Positive top-line results from the Phase IIb DOVE study of Scynexis's SCY-078, and progress with a new intravenous formulation, suggest the US biotech's new triterpenoid could be the first of a new class of antifungal agents for serious infections.

 

Clinical Trials Gynecology & Urology
See All
UsernamePublicRestriction

Register